Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The comp...

Regeneron Pharmaceuticals Inc (REGN) has a valuation score of 67/100 (moderate), profitability score of 82/100 (strong), financial health score of 100/100 (strong), Piotroski F-Score of 5/9, Altman Z-Score of 7.21 (safe zone), revenue growth of +5.6% YoY.

Neutral

Analyst Consensus

Strong Buy

Wall Street consensus estimates — not a PMP forecast · Updated Sep 1, 2026

Analyst Recommendations37 analysts · 2026-08-01
8
18
11
Strong Buy 8Buy 18Hold 11Sell 0Strong Sell 0

Recent Market Moves

See all REGN moves →
DateSessionPriceMoveZ-Score
Aug 27Pre-market$814.79-2.82%-2.05
Aug 26After-hours$810.09-2.82%-2.05
Regeneron Pharmaceuticals Inc (REGN) Valuation & P/E History →Regeneron Pharmaceuticals Inc (REGN) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →